Prosecution Insights
Last updated: November 20, 2026
Application No. 18/288,734

METHODS FOR TREATING AND MONITORING PARKINSON'S DISEASE

Final Rejection §103§DOUBLEPATENT
Filed
Oct 27, 2023
Priority
Apr 30, 2021 — provisional 63/182,207 +1 more
Examiner
WHITE, DAWANNA SHAR-DAY
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Denali Therapeutics Inc.
OA Round
2 (Final)
63%
Grant Probability
Moderate
3-4
OA Rounds
4m
Est. Remaining
84%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
82 granted / 130 resolved
+3.1% vs TC avg
Strong +21% interview lift
Without
With
+21.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
59 currently pending
Career history
203
Total Applications
across all art units

Statute-Specific Performance

§101
3.6%
-36.4% vs TC avg
§103
34.9%
-5.1% vs TC avg
§102
13.9%
-26.1% vs TC avg
§112
21.4%
-18.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 130 resolved cases

Office Action

§103 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . All previous objections and rejections not reiterated herein were overcome by claim amendments, filed August 19th, 2026, that have been fully considered and found persuasive. As such all objections and rejections not reiterated herein have been withdrawn. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1, 4, 14 – 16, 30, 35 – 36, 49 – 50, and 53 – 58 are rejected under 35 U.S.C. 103 as being unpatentable over US Patent Application Publication US 2017/0362206 A1 to Estrada et. al. (Estrada’206; cited on the ISR form). Regarding claims 1, 4, 14 – 16, 30, 35 – 36, 49 – 50, and 53 – 58, Estrada’206 teach novel heteroaryl-substituted pyrimidines and their use as therapeutic agents as inhibitors of LRRK2. See page 1 paragraph 0002. Additionally, Estrada’206 teach pharmaceutical compositions, kits that include the compounds, and methods of using (or administering) and making the compounds of the present disclosure. See page 1 paragraph 0006. See claims 1, and 35. Estrada’206 teach compounds of formula I of structure PNG media_image1.png 178 162 media_image1.png Greyscale . See page 1 paragraph 0007. Specifically, Estrada’206 teach compound No. 78 of structure PNG media_image2.png 200 400 media_image2.png Greyscale . See page 34 Table 1B-contitnued 1st column 2nd row. See claims 1, and 35. Furthermore, Estrada’206 teach that the disease or condition mediated, at least in part by LRRK2 is a neurodegenerative disease which includes Parkinson's disease (PD), Alzheimer's disease (AD), dementia (including Lewy body dementia and vascular dementia), amyotrophic lateral sclerosis (ALS). See page 54 paragraph 0285. See claim 1. Moreover, Estrada’206 teach that the disease or condition mediated, at least in part by LRRK2 also include cancers such as those of the thyroid, renal (including papillary renal), breast, lung, blood, and prostate cancers (e.g. solid tumor), leukemias (including acute myelogenous leukemia (AML)), or lymphomas. See page 55 paragraph 0286. Estrada’206 teach that pharmaceutical compositions comprising compound no. 78 can be administered in either single or multiple doses. See page 56 paragraph 0299. See claims 15 – 16, 20, and 50. Furthermore, Estrada’206 teach that pharmaceutical composition comprising compound 78 can administered orally. See page 56 paragraph 0299. See claims 14, and 49. Additionally, Estrada’206 teach that pharmaceutical composition comprising compound 78 include the active ingredient diluted by an excipient and/or enclosed within such a carrier that can be in the form of a capsule, sachet, paper or other container. See page 56 paragraph 0301. See claim 35. Estrada’206 teach that when compositions comprising compound 78 are administered orally, the total daily dosage for a human subject can be between 1 mg and 1,000 mg, between about 1,000-2,000 mg/day, between about 10-500 mg/day, between about 50-300 mg/day, between about 75-200 mg/day, or between about 100-150 mg/day. See page 57 paragraph 0309. See claims 1, 4, 30, 35 – 36, and 53 – 58. Moreover, Estrada’206 teach that compounds of the present application or the compositions thereof can be administered once, twice, three, four, or more times daily. See page 57 paragraph 0310. See claims 15 – 16, and 50. Regarding claim 1 limitation for a method for treating Parkinson's disease, the method comprising administering to a subject in need thereof about 75 mg, about 80 mg, about 105 mg, about 130 mg, about 150 mg, about 225 mg, about 250 mg, or about 300 mg; as taught above, Estrada’206 teach that when compositions comprising compound 78 are administered orally, the total daily dosage for a human subject can be between 1 mg and 1,000 mg, between about 1,000-2,000 mg/day, between about 10-500 mg/day, between about 50-300 mg/day, between about 75-200 mg/day, or between about 100-150 mg/day. See page 57 paragraph 0309. Thus Estarda’206 teach that compound 78, which is identical to the compound of the examined claims, can be administered in ranges that encompasses the specific amounts recited. Thus in the case where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990). See MPEP 2144.05 (I). Regarding claim 35 limitation for a pharmaceutical composition comprising about 75 mg, about 80 mg, about 105 mg, about 130 mg, about 150 mg, about 225 mg, about 250 mg, or about 300 mg; as taught above, Estrada’206 teach that compositions comprising compound 78 can be administered orally, the total daily dosage for a human subject can be between 1 mg and 1,000 mg, between about 1,000-2,000 mg/day, between about 10-500 mg/day, between about 50-300 mg/day, between about 75-200 mg/day, or between about 100-150 mg/day. See page 57 paragraph 0309. Thus Estarda’206 teach that compound 78, which is identical to the compound of the examined claims, can be administered in ranges that encompasses the specific amounts recited. Thus in the case where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990). See MPEP 2144.05 (I). Claims 17 – 18 are rejected under 35 U.S.C. 103 as being unpatentable over US Patent Application Publication US 2017/0362206 A1 to Estrada et. al. (Estrada’206; cited on the ISR form) in view of Atashrazm et. al. ((2018), LRRK2-Mediated Rab10 Phosphorylation in Immune Cells From Parkinson’s Disease Patients, Movement Disorder, 34, 406 – 415; cited on the ISR). The teachings of Estrada’206 as they relate to claim 1, from which claims 17 – 18 depend, are given previously in this office action and are fully incorporated here. However, Estrada’206 fail to teach a method for treating Parkinson’s disease where the method results in a reduction in phosphorylated S935 LRRK2 (pS935) in whole blood of a subject. See claim 17. Estrada’206 fail to teach a method for treating Parkinson’s disease where the method results in a reduction in phosphorylated ras-related protein Rab 10 (pRab 10) in peripheral blood mononuclear cells (PBMC) of a subject. See claim 18. Nevertheless, Atashrazm et. al. teach that leucine-rich repeat kinase 2 (LRRK2) has emerged as a promising therapeutic target for the treatment of Parkinson’s disease (PD). See page 407 column 1 paragraph 1. Atashrazm et. al. teach that in vitro LRRK2 activity assays demonstrated that the most common pathogenic missense mutation, G2019S, increased the enzyme’s catalytic kinase activity. See page 407 column 1 paragraph 2. Additionally, Atashrazm et. al. teach that the most robust LRRK2 substrate is Rab10, which is phosphorylated on threonine 73, a residue in the switch II region of Rab10 that appears important for regulating Rab10 protein interactions and subcellular localization. See page 407 column 1 paragraph 3. Furthermore, Atashrazm et. al. teach that Rab10 is expressed in peripheral blood cells including B-lymphocytes, monocytes, and neutrophils, and in healthy controls, Rab10 phosphorylation is decreased in these cell types by ex vivo LRRK2 inhibitor treatment. See page 407 column 1 paragraph 3. See claim 18. Moreover, Atashrazm et. al. teach that the current gold standard readout of LRRK2 inhibitor target engagement is to monitor reduced phosphorylation of serine 935, a residue on the LRRK2 protein that is required for interaction with 14-3-3 protein family members. See page 407 column 1 paragraph 4. See claim 17. Atashrazm et. al. teach that the use of LRRK2 serine 935 as a peripheral readout of LRRK2 inhibitor target engagement has been further validated in PD cohorts. See page 407 column 1 paragraph 4. Atashrazm et. al. teach that phosphorylation on this residue is complexly regulated, including phosphorylation by other kinases and counter-regulation by phosphatases. See page 407 column 1 paragraph 4. Hence, Atashrazm et. al. teach that for a clinical trial of LRRK2 inhibitors, it would therefore be prudent to include a second readout of inhibitor target engagement. See page 407 column 2 paragraph 1. Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the instant application to modify the method of Estrada’206 for treating Parkinson’s disease using prior art compound 78 in view of Atashrazm et. al., that is to monitor for a reduction of phosphorylated S935 LRRK2 (pS935) and a reduction in phosphorylated ras-related protein Rab 10 (pRab 10). One of ordinary skill in the art would have been motivated to make this modification because phosphorylation on the S935 LRRK2 is complexly regulated, including through phosphorylation by other kinases and counter-regulation by phosphatases. Moreover, one of ordinary skill in the art would have had reasonable expectation of success because Rab10 phosphorylation is decreased in these cell types by ex vivo LRRK2 inhibitor treatment. Claim 19 is rejected under 35 U.S.C. 103 as being unpatentable over US Patent Application Publication US 2017/0362206 A1 to Estrada et. al. (Estrada’206; cited on the ISR form) in view of Alcalay et. al. ((2019), Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development, Movement Disorder, 35, 134 – 141; cited on the ISR). The teachings of Estrada’206 as they relate to claim 1, from which claim 19 depends, are given previously in this office action and are fully incorporated here. However, Estrada’206 fail to teach a method for treating Parkinson’s disease where the method results in a reduction of lysosomal lipid 22:6-bis[monoacylglycerol]phosphate (BMP) in urine of the subject. See claim 19. Nevertheless, Alcalay et. al. teach that mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2) are among the most common genetic causes of Parkinson’s disease (PD). See page 135 column 1 paragraph 1. Alcalay et. al. teach that bis(monoacylglycerol) phosphate (BMP) isoforms are localized within the inner membranes of late endosomes (multivesicular bodies) and lysosomes, where they contribute to the multivesicular/lamellar morphology of the Endo lysosomal network. See page 135 column 1 paragraph 3. Moreover, Alcalay et. al. teach that didocosahexaenoyl(22:6)-BMP (di-22:6-BMP), a specific species of BMP, is decreased in the urine of LRRK2-knockout mice and in non-human primates treated with chemically distinct LRRK2 kinase inhibitors (PFE-360, MLi-2, and GNE-7915), directly implicating its utility as a biomarker of LRRK2 activity. See page 135 column 1 paragraph 3. Alcalay et. al. teach that there was a correlational analyses indicated that total di-18:1-BMP and total di-22:6-BMP most strongly discriminated the LRRK2 mutation carriers from non-carriers. See page 136 column 2 paragraph 4. Moreover, Alcalay et. al. teach that among PD patients, higher di- 22:6-BMP (total levels and 2,20 isoform levels) were associated with worse cognitive performance on the Montreal Cognitive Assessment (MoCA) suggesting that BMP isoforms may be biomarkers of pathophysiology of PD. See page 138 column 1 paragraph 3. Additionally, Alcalay et. al. teach that the utility of urinary BMP as a biomarker to monitor disease progression and as a pharmacodynamic biomarker to demonstrate LRRK2 kinase modulation by drug candidates. See page 140 column 2 paragraph 2. Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the instant application to modify the method of Estrada’206 for treating Parkinson’s disease using prior art compound 78 in view of Alcalay et. al., that is to monitor for a reduction of lysosomal lipid 22:6-bis[monoacylglycerol]phosphate (BMP) in urine. One of ordinary skill in the art would have been motivated to make this modification because higher di- 22:6-BMP in the subjects urine was associated with worse cognitive performance on the Montreal Cognitive Assessment (MoCA). Moreover, one of ordinary skill in the art would have had reasonable expectation of success because di-22:6-BMP most strongly discriminated the LRRK2 mutation carriers from non-carriers. Claim 31 is rejected under 35 U.S.C. 103 as being unpatentable over US Patent Application Publication US 2017/0362206 A1 to Estrada et. al. (Estrada’206; cited on the ISR form) in view of Kluss et. al. ((2019), LRRK2 links genetic and sporadic Parkinson’s disease, Biochemical Society Transactions, 47, 651 – 661; cited in the office action dated May 19th, 2026). The teachings of Estrada’206 as they relate to claim 1, from which claim 31 depend, are given previously in this office action and are fully incorporated here. However, Estrada’206 fail to teach a method for treating Parkinson’s disease where the Parkinson's disease is familial, or sporadic. See claim 31. Nevertheless, Kluss et. al. teach that Parkinson’s disease (PD) is a neurodegenerative disorder affecting over 4 million people over the age of 50 within the world’s top 15 most populated countries, and that number is expected to double by 2030. See page 651 paragraph 1. Kluss et.al. teach that although ∼90% of PD cases are sporadic (sPD), that is having no clearly defined single cause, the remaining 10% show a clear family history and are thus considered monogenic PD, that is familial. See page 651 paragraph 1. Kluss et. al. teach that patients carrying mutations in the Leucine-rich repeat kinase 2 (LRRK2) gene, one of the most common genetic contributors of PD, manifest clinical features which are almost indistinguishable from the sporadic form. See page 651 paragraph 2. Moreover, Kluss et. al. teach that both forms have similar patterns of motor symptoms which include the hallmark bradykinesia, tremor, rigidity, and postural instability have been reported. See page 651 paragraph 2. Furthermore, Kluss et. al. teach that nonmotor symptoms which include hallucinations, depression, anxiety, cognitive impairment, and pain also appear in both familial and sporadic PD. See page 651 paragraph 2. Thus Kluss et. al. teach that there are convergent pathways that drive neuropathology in both familial and sporadic PD with a potential common cellular pathway of dysfunction. See page 651 paragraph 2. Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the instant application to modify the method of Estrada’206 for treating Parkinson’s disease using prior art compound 78 in view of Kluss et. al., that is to treat either familial or sporadic Parkinson’s disease. One of ordinary skill in the art would have been motivated to make this modification because either form has similar patterns of motor symptoms which include the hallmark bradykinesia, tremor, rigidity, and postural instability. Moreover, one of ordinary skill in the art would have had reasonable expectation of success because the prior art suggest that familial and sporadic PD have convergent pathways that drive neuropathology with a potential common cellular pathway of dysfunction. Response to Arguments Applicant's arguments filed August 19th, 2026 with regards to the prior art rejection of claims 1, 4, 14 – 19, 30 – 31, 35 – 36, 49 – 50, and 53 – 58 have been fully considered but they are not persuasive. Applicants argues that the primary reference of Estrada’206 does not disclose the specific dosage of about 75 mg, about 80 mg, about 105 mg, about 130 mg, about 150 mg, about 225 mg, about 250 mg, or about 300 mg of amended claim 1. See Applicant’s argument page 6 paragraph 1. Moreover, applicant argues that as demonstrated in the specification the claimed dose selections provide meaningful in vivo effects on biomarkers of LRRK2 kinase activity and lysosomal function which is not taught by the prior art reference of Estrada’206, Atashrazm et. al., Alcalay et. al., and Kluss et. al. See Applicant’s argument page 7 paragraph 1. The examiner contends that that the prior art of Estrada’206 does teach compositions comprising compound 78 in dosages of between 1 mg and 1,000 mg, between about 1,000-2,000 mg/day, between about 10-500 mg/day, between about 50-300 mg/day, between about 75-200 mg/day, or between about 100-150 mg/day. See page 57 paragraph 0309. Thus, as stated above in the prior art rejection, Estarda’206 teach that compound 78, which is identical to the compound of the examined claims, can be administered in ranges that encompasses the specific amounts recited. Thus in the case where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990). See MPEP 2144.05 (I). Moreover, the examiner contends that generally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). See MPEP 2144.05(II)(A). Therefore given that the skill of one of ordinary skill in the pharmaceutical arts is relatively high being that of a Ph. D., MD, or Pharm D. it would be within the purview of such artisan through the course of administering compound 78 to determine what the optimal dosage is for the patient and through routine optimization administer the recited mg dosages. Furthermore, the examiner contends that the prior art of Atashrazm et. al., and Alcalay et. al. renders obvious the in vivo effects on biomarkers of LRRK2 kinase activity and lysosomal function by specifically teaching that the effects are the direct result of the inhibiting LRRK2 kinase activity. Specifically, as taught above, Atashrazm et. al. teach that Rab10 is expressed in peripheral blood cells including B-lymphocytes, monocytes, and neutrophils, and in healthy controls, Rab10 phosphorylation is decreased in these cell types by ex vivo LRRK2 inhibitor treatment. See page 407 column 1 paragraph 3. Additionally, as taught above, Atashrazm et. al. teach that the current gold standard readout of LRRK2 inhibitor target engagement is to monitor reduced phosphorylation of serine 935, a residue on the LRRK2 protein that is required for interaction with 14-3-3 protein family members. See page 407 column 1 paragraph 4. Thus, Atashrazm et. al. suggest that it was well established in the art that the inhibition of LRRK2 leads to a reduction in the phosphorylation of serine 935, a residue on the LRRK2 protein. Moreover, Alcalay et. al. teach that didocosahexaenoyl(22:6)-BMP (di-22:6-BMP), a specific species of BMP, is decreased in the urine of LRRK2-knockout mice and in non-human primates treated with chemically distinct LRRK2 kinase inhibitors (PFE-360, MLi-2, and GNE-7915), directly implicating its utility as a biomarker of LRRK2 activity. See page 135 column 1 paragraph 3. Thus the prior art of Atashrazm et. al., and Alcalay et. al. teach that the reduction in pS935 LRRK2, PRAB10, and didocosahexaenoyl(22:6)-BMP (di-22:6-BMP) are in vivo effects specific to the inhibition of LRRK2 kinase activity. Thus the prior art rejection of claims 1, 4, 14 – 19, 30 – 31, 35 – 36, 49 – 50, and 53 – 58 is maintained, deemed proper, and made final. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 4, 14 – 19, 30 – 31, 35 – 36, 49 – 50, and 53 – 58 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 – 5, 9, 11 – 14, 16 – 17, 19 – 20, and 25 – 26, of U.S. Patent No. US 9932325 B2 to Estrada et. al. (Estrada’325; cited on the IDS) in view of US Patent Application Publication US 2017/0362206 A1 to Estrada et. al. (Estrada’206; cited on the ISR form), Atashrazm et. al. ((2018), LRRK2-Mediated Rab10 Phosphorylation in Immune Cells From Parkinson’s Disease Patients, Movement Disorder, 34, 406 – 415; cited on the ISR), Alcalay et. al. ((2019), Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development, Movement Disorder, 35, 134 – 141; cited on the ISR), and Kluss et. al. ((2019), LRRK2 links genetic and sporadic Parkinson’s disease, Biochemical Society Transactions, 47, 651 – 661; cited in the office action dated May 19th, 2026). Estrada’325 recite a compound of formula Ia: compound of formula Ia: PNG media_image3.png 198 194 media_image3.png Greyscale . See reference claim 1. Specifically, Estrada’114 recite the compound PNG media_image2.png 200 400 media_image2.png Greyscale . See reference claims 1 – 5, 9, 11 – 14, 16 – 17, and 19. See instant claim 1, and 35. Additionally, Estrada’114 recite a pharmaceutical composition comprising the above compound and a pharmaceutically acceptable carrier, diluent, or excipient. See reference claims 20, and 25 – 26. See instant claim 35. However, Estrada’325 fail to recite a method of treating Parkinson’s disease comprising administering to a subject in need thereof about 75 mg, about 80 mg, about 105 mg, about 130 mg, about 150 mg, about 225 mg, about 250 mg, or about 300 mg of compound I above or a pharmaceutically acceptable salt or deuterated analog thereof. See instant claim 1. Furthermore, Estrada’325 fail to recite a pharmaceutical composition comprising about 75 mg, about 80 mg, about 105 mg, about 130 mg, about 150 mg, about 225 mg, about 250 mg, or about 300 mg of compound I above or a pharmaceutically acceptable salt or deuterated analog thereof and a pharmaceutically acceptable carrier. See instant claim 35. The teachings of Estrada’206, Atashrazm et. al., Alcalay et. al., and Kluss et. al. as they relate to the prior art rejection of instant claims 1, 4, 14 – 19, 30 – 31, 35 – 36, 49 – 50, and 53 – 58, are given previously in this office action and are fully incorporated here. Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the instant application to modify the invention of Estrada’325 a compound of formula Ia in view of Estrada’206, that is for a method comprising administering about 75 mg, about 80 mg, about 105 mg, about 130 mg, about 150 mg, about 225 mg, about 250 mg, or about 300 mg of the above compound in view of Atashrazm et. al., that is to monitor for a reduction of phosphorylated S935 LRRK2 (pS935) and a reduction in phosphorylated ras-related protein Rab 10 (pRab 10); in view of Alcalay et. al., that is to monitor for a reduction of lysosomal lipid 22:6-bis[monoacylglycerol]phosphate (BMP) in urine; and further in view of Kluss et. al., that is to treat either familial or sporadic Parkinson’s disease. One of ordinary skill in the art would have been motivated to make this modification because phosphorylation on the S935 LRRK2 is complexly regulated, including through phosphorylation by other kinases and counter-regulation by phosphatases. Moreover, one of ordinary skill in the art would have had reasonable expectation of success because Rab10 phosphorylation is decreased in these cell types by ex vivo LRRK2 inhibitor treatment. One of ordinary skill in the art would have been motivated to make this modification because higher di- 22:6-BMP in the subjects urine was associated with worse cognitive performance on the Montreal Cognitive Assessment (MoCA). Moreover, one of ordinary skill in the art would have had reasonable expectation of success because di-22:6-BMP most strongly discriminated the LRRK2 mutation carriers from non-carriers. One of ordinary skill in the art would have been motivated to make this modification because either form has similar patterns of motor symptoms which include the hallmark bradykinesia, tremor, rigidity, and postural instability. Moreover, one of ordinary skill in the art would have had reasonable expectation of success because the prior art suggest that familial and sporadic PD have convergent pathways that drive neuropathology with a potential common cellular pathway of dysfunction. Claims 1, 4, 14 – 19, 30 – 31, 35 – 36, 49 – 50, and 53 – 58 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 – 5, 9, 11 – 14, 17, 19, and 22 of U.S. Patent No. US 10590114 B2 to Estrada et. al. (Estrada’114; cited on the IDS) in view of US Patent Application Publication US 2017/0362206 A1 to Estrada et. al. (Estrada’206; cited on the ISR form), Atashrazm et. al. ((2018), LRRK2-Mediated Rab10 Phosphorylation in Immune Cells From Parkinson’s Disease Patients, Movement Disorder, 34, 406 – 415; cited on the ISR), Alcalay et. al. ((2019), Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development, Movement Disorder, 35, 134 – 141; cited on the ISR), and Kluss et. al. ((2019), LRRK2 links genetic and sporadic Parkinson’s disease, Biochemical Society Transactions, 47, 651 – 661; cited in the office action dated May 19th, 2026). Estrada’114 recite a method for treating a disease or condition mediated, at least in part, by LRRK2, wherein the disease or condition is selected from the group consisting of Parkinson's disease, dementia, Alzheimer' s disease, L-Dopa induced dyskinesia, and amyotrophic lateral sclerosis, the method comprising administering to a subject in need thereof an effective amount of a compound of formula Ia: PNG media_image3.png 198 194 media_image3.png Greyscale . See reference claim 1. See instant claim 1. Specifically, Estrada’114 recite a method where the compound is PNG media_image2.png 200 400 media_image2.png Greyscale . See reference claims 1 – 5, 9, 11 – 14, 17, 19, and 22. See instant claim 1, and 35. However, Estrada’114 fail to recite a method of treating Parkinson’s disease comprising administering to a subject in need thereof about 75 mg, about 80 mg, about 105 mg, about 130 mg, about 150 mg, about 225 mg, about 250 mg, or about 300 mg of compound I above or a pharmaceutically acceptable salt or deuterated analog thereof. See instant claim 1. Furthermore, Estrada’114 fail to recite a pharmaceutical composition comprising about 75 mg, about 80 mg, about 105 mg, about 130 mg, about 150 mg, about 225 mg, about 250 mg, or about 300 mg of compound I above or a pharmaceutically acceptable salt or deuterated analog thereof and a pharmaceutically acceptable carrier. See instant claim 35. The teachings of Estrada’206, Atashrazm et. al., Alcalay et. al., and Kluss et. al. as they relate to the prior art rejection of instant claims 1, 4, 14 – 19, 30 – 31, 35 – 36, 49 – 50, and 53 – 58, are given previously in this office action and are fully incorporated here. Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the instant application to modify the invention of Estrada’114 for a method for treating a disease or condition mediated, at least in part, by LRRK2, which is Parkinson’s disease in view of Estrada’206, that is for a method comprising administering about 75 mg, about 80 mg, about 105 mg, about 130 mg, about 150 mg, about 225 mg, about 250 mg, or about 300 mg of the above compound in view of Atashrazm et. al., that is to monitor for a reduction of phosphorylated S935 LRRK2 (pS935) and a reduction in phosphorylated ras-related protein Rab 10 (pRab 10); in view of Alcalay et. al., that is to monitor for a reduction of lysosomal lipid 22:6-bis[monoacylglycerol]phosphate (BMP) in urine; and further in view of Kluss et. al., that is to treat either familial or sporadic Parkinson’s disease. One of ordinary skill in the art would have been motivated to make this modification because phosphorylation on the S935 LRRK2 is complexly regulated, including through phosphorylation by other kinases and counter-regulation by phosphatases. Moreover, one of ordinary skill in the art would have had reasonable expectation of success because Rab10 phosphorylation is decreased in these cell types by ex vivo LRRK2 inhibitor treatment. One of ordinary skill in the art would have been motivated to make this modification because higher di- 22:6-BMP in the subjects urine was associated with worse cognitive performance on the Montreal Cognitive Assessment (MoCA). Moreover, one of ordinary skill in the art would have had reasonable expectation of success because di-22:6-BMP most strongly discriminated the LRRK2 mutation carriers from non-carriers. One of ordinary skill in the art would have been motivated to make this modification because either form has similar patterns of motor symptoms which include the hallmark bradykinesia, tremor, rigidity, and postural instability. Moreover, one of ordinary skill in the art would have had reasonable expectation of success because the prior art suggest that familial and sporadic PD have convergent pathways that drive neuropathology with a potential common cellular pathway of dysfunction. Claims 1, 4, 14 – 19, 30 – 31, 35 – 36, 49 – 50, and 53 – 58 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 – 5, 9, 11, 13 – 14, 16, 19, and 22 of U.S. Patent No. US 11111235 B2 to de Vicente Fildalgo et. al. (de Vicente Fildalgo’235; cited on the IDS) in view of US Patent Application Publication US 2017/0362206 A1 to Estrada et. al. (Estrada’206; cited on the ISR form), Atashrazm et. al. ((2018), LRRK2-Mediated Rab10 Phosphorylation in Immune Cells From Parkinson’s Disease Patients, Movement Disorder, 34, 406 – 415; cited on the ISR), Alcalay et. al. ((2019), Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development, Movement Disorder, 35, 134 – 141; cited on the ISR), and Kluss et. al. ((2019), LRRK2 links genetic and sporadic Parkinson’s disease, Biochemical Society Transactions, 47, 651 – 661; cited in the office action dated May 19th, 2026). de Vicente Fildalgo’235 recite a method for treating a disease or condition mediated, at least in part, by LRRK2, wherein the disease or condition is selected from the group consisting of kidney cancer, breast cancer, prostate cancer, blood cancer, papillary cancer, lung cancer, acute myelogenous leukemia, multiple myeloma, leprosy, Crohn's disease, inflammatory bowel disease, ulcerative colitis, rheumatoid arthritis, and ankylosing spondylitis, the method comprising administering to a subject in need thereof an effective amount of a compound of formula Ia PNG media_image3.png 198 194 media_image3.png Greyscale . See reference claim 1. Specifically, de Vicente Fildalgo’235 recite a method where the compound is PNG media_image2.png 200 400 media_image2.png Greyscale . See reference claims 1 – 5, 9, 11, 13 – 14, 16, 19, and 22. See instant claim 1, and 35. However, de Vicente Fildalgo’235 fail to recite a method of treating Parkinson’s disease comprising administering to a subject in need thereof about 75 mg, about 80 mg, about 105 mg, about 130 mg, about 150 mg, about 225 mg, about 250 mg, or about 300 mg of compound I above or a pharmaceutically acceptable salt or deuterated analog thereof. See instant claim 1. Furthermore, de Vicente Fildalgo’235 fail to recite a pharmaceutical composition comprising about 75 mg, about 80 mg, about 105 mg, about 130 mg, about 150 mg, about 225 mg, about 250 mg, or about 300 mg of compound I above or a pharmaceutically acceptable salt or deuterated analog thereof and a pharmaceutically acceptable carrier. See instant claim 35. The teachings of Estrada’206, Atashrazm et. al., Alcalay et. al., and Kluss et. al. as they relate to the prior art rejection of instant claims 1, 4, 14 – 19, 30 – 31, 35 – 36, 49 – 50, and 53 – 58, are given previously in this office action and are fully incorporated here. Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the instant application to modify the invention of Estrada’325 for a method for treating a disease or condition mediated, at least in part, by mediated LRRK2, in view of Estrada’206, that is where the disease or condition mediated, at least in part, by mediated LRRK2 is Parkinson Disease further comprising administering about 75 mg, about 80 mg, about 105 mg, about 130 mg, about 150 mg, about 225 mg, about 250 mg, or about 300 mg of the above compound in view of Atashrazm et. al., that is to monitor for a reduction of phosphorylated S935 LRRK2 (pS935) and a reduction in phosphorylated ras-related protein Rab 10 (pRab 10); in view of Alcalay et. al., that is to monitor for a reduction of lysosomal lipid 22:6-bis[monoacylglycerol]phosphate (BMP) in urine; and further in view of Kluss et. al., that is to treat either familial or sporadic Parkinson’s disease. One of ordinary skill in the art would have been motivated to make this modification because phosphorylation on the S935 LRRK2 is complexly regulated, including through phosphorylation by other kinases and counter-regulation by phosphatases. Moreover, one of ordinary skill in the art would have had reasonable expectation of success because Rab10 phosphorylation is decreased in these cell types by ex vivo LRRK2 inhibitor treatment. One of ordinary skill in the art would have been motivated to make this modification because higher di- 22:6-BMP in the subjects urine was associated with worse cognitive performance on the Montreal Cognitive Assessment (MoCA). Moreover, one of ordinary skill in the art would have had reasonable expectation of success because di-22:6-BMP most strongly discriminated the LRRK2 mutation carriers from non-carriers. One of ordinary skill in the art would have been motivated to make this modification because either form has similar patterns of motor symptoms which include the hallmark bradykinesia, tremor, rigidity, and postural instability. Moreover, one of ordinary skill in the art would have had reasonable expectation of success because the prior art suggest that familial and sporadic PD have convergent pathways that drive neuropathology with a potential common cellular pathway of dysfunction. Response to Arguments Applicant's arguments filed August 19th, 2026 with regards to the nonstatutory double patenting (NSDP) rejection of claims 1, 4, 14 – 19, 30 – 31, 35 – 36, 49 – 50, and 53 – 58 have been fully considered but they are not persuasive. Applicants arguments in regard to the NSDP rejection of claims 1, 4, 14 – 19, 30 – 31, 35 – 36, 49 – 50, and 53 – 58 are identical to the arguments for the prior art rejection. Therefore the examiners response to the NSDP rejection arguments have been addressed in the response to the prior art rejection arguments given previously in this office action. Thus the NSDP rejections of instant claims 1, 4, 14 – 19, 30 – 31, 35 – 36, 49 – 50, and 53 – 58 are maintained, deemed proper, and made final. Conclusion Claims 1, 4, 14 – 19, 30 – 31, 35 – 36, 49 – 50, and 53 – 58 are rejected. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DAWANNA S WHITE whose telephone number is (703)756-4687. The examiner can normally be reached 7:00 am - 5:00 pm [EST] M - Th. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached at 571-270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DAWANNA SHAR-DAY WHITE/Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

Oct 27, 2023
Application Filed
May 19, 2026
Non-Final Rejection mailed — §103, §DOUBLEPATENT
Aug 19, 2026
Response Filed
Nov 02, 2026
Final Rejection mailed — §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790323
CDK19-Selective Inhibitors, and Methods of Use Thereof
3y 9m to grant Granted Nov 10, 2026
Patent 12780807
NOVEL DIPHENAZINE COMPOUND, AND USE THEREOF FOR PREVENTING OR TREATING CANCER OR NEUROINFLAMMATORY DISEASES
2y 11m to grant Granted Nov 03, 2026
Patent 12758553
USE OF POZIOTINIB FOR THE TREATMENT OF CANCERS WITH NRG1 FUSIONS
4y 2m to grant Granted Oct 13, 2026
Patent 12753161
PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE
4y 0m to grant Granted Oct 06, 2026
Patent 12753163
DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1
3y 5m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
63%
Grant Probability
84%
With Interview (+21.1%)
3y 5m (~4m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 130 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month